A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction
NCT ID: NCT00665496
Last Updated: 2014-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
732 participants
INTERVENTIONAL
2003-06-30
2003-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Levitra (Vardenafil, BAY38-9456)
Vardenafil 10 mg and 20 mg orally once a day as needed
Arm 2
Placebo
Matching Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levitra (Vardenafil, BAY38-9456)
Vardenafil 10 mg and 20 mg orally once a day as needed
Placebo
Matching Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Heterosexual relationship
* 18 years and older
Exclusion Criteria
* History of myocardial infarction, stroke or life threatening arrhythmia within the prior 6 months
* Nitrates or nitric oxide donors use
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Beverly Hills, California, United States
San Bernardino, California, United States
Aurora, Colorado, United States
Trumbull, Connecticut, United States
Aventura, Florida, United States
Jacksonville, Florida, United States
Pembroke Pines, Florida, United States
Lawrenceville, New Jersey, United States
New York, New York, United States
Charlotte, North Carolina, United States
Wilmington, North Carolina, United States
Calgary, Alberta, Canada
Winnipeg, Manitoba, Canada
Saint John, New Brunswick, Canada
Kentville, Nova Scotia, Canada
Barrie, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Sherbrooke, Quebec, Canada
Carpentras, , France
Lille, , France
Lyon, , France
Lyon, , France
Marseille, , France
Montpellier, , France
Nîmes, , France
Paris, , France
Garmisch-Partenkirchen, Bavaria, Germany
München, Bavaria, Germany
München, Bavaria, Germany
Hamburg, City state of Hamburg, Germany
Marburg, Hesse, Germany
Hanover, Lower Saxony, Germany
Osnabrück, Lower Saxony, Germany
Westerstede, Lower Saxony, Germany
Düsseldorf, North Rhine-Westphalia, Germany
Mönchengladbach, North Rhine-Westphalia, Germany
Niederkassel, North Rhine-Westphalia, Germany
Leipzig, Saxony, Germany
Halle, Saxony-Anhalt, Germany
Milan, , Italy
Milan, , Italy
Modena, , Italy
Napoli, , Italy
Padua, , Italy
Amsterdam, , Netherlands
Nijmegen, , Netherlands
Roermond, , Netherlands
The Hague, , Netherlands
Utrecht, , Netherlands
Moelv, , Norway
Oslo, , Norway
Sarpsborg, , Norway
Trondheim, , Norway
Warsaw, Poland, Poland
Kościerzyna, , Poland
Lodz, , Poland
Poznan, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Badalona, Barcelona, Spain
Barcelona, Barcelona, Spain
L'Hospitalet de Llobregat, Barcelona, Spain
Galdakao, Bizkaia, Spain
Castellon, Castellón de La Plana, Spain
Barcelona, Catalonia, Spain
Madrid, Madrid, Spain
Zaragoza, Zaragoza, Spain
Borås, , Sweden
Gothenburg, , Sweden
Skövde, , Sweden
Stockholm, , Sweden
Bristol, Avon, United Kingdom
Bristol, Avon, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONTIME
Identifier Type: -
Identifier Source: secondary_id
100492
Identifier Type: -
Identifier Source: org_study_id